Mercaptopurine (Page 3 of 3)
HOW SUPPLIED
Light yellow to off white, diamond shaped, scored tablets containing 50 mg mercaptopurine, debossed with “P02 ”; bottles of 60 (NDC 49884-922-02), and 250 (NDC 49884-922-04).
Store at 20° to 25°C (68°to 77°F) in a dry place. See USP controlled room temperature.
REFERENCES
- 1.
- ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA: Oncology Nursing Society; 1999:32-41.
- 2.
- Recommendations for the safe handling of parenteral antineoplastic drugs. Washington, DC: Division of Safety; Clinical Center Pharmacy Department and Cancer Nursing Services, National Institutes of Health; 1992. US Dept of Health and Human Services. Public Health Service publication NIH 92-2621.
- 3.
- AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA. 1985; 253:1590-1591.
- 4.
- National Study Commission on Cytotoxic Exposure. Recommendations for handling cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.
- 5.
- Clinical Oncological Society of Australia. Guidelines and recommendations for safe handling of antineoplastic agents. Med J Australia. 1983; 1:426-428.
- 6.
- Jones RB, Frank R, Mass T. Safe handling of chemotherapeutic agents: a report from the Mount Sinai Medical Center. CA-A Cancer J for Clinicians. 1983;33:258-263.
- 7.
- American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990;47:1033-1049.
- 8.
- Controlling Occupational Exposure to Hazardous Drugs. (OSHA Work-Practice Guidelines.) Am J Health-Syst Pharm. 1996;53:1669-1685.
Distributed by:
PAR PHARMACEUTICAL COMPANIES, INC.
Spring Valley, NY 10977
ZYLOPRIM® is a registered trademark of Prometheus Laboratories Inc.
Revised: 05/12
OS922-02-1-06
MR001C
Principal Display Panel
50mg 60 tablets bottle
NDC 49884-922-02
Mercaptopurine Tablets,
USP
50 mg
Rx only
Cytotoxic agent
60 Tablets
Par Pharmaceutical
MERCAPTOPURINE mercaptopurine tablet | ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
| ||||||||||||||||||
|
Labeler — Par Pharmaceutical Inc. (092733690) |
Registrant — Par Pharmaceutical Inc. (092733690) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Stason Pharmaceuticals, Inc. | 807437553 | MANUFACTURE (49884-922) |
Revised: 01/2015 Par Pharmaceutical Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.